Published Date: 20 Mar 2024
Breast cancer that manifests in between two screening program reviews is known as interval breast cancer. In other words, a negative test result precedes the next evaluation and the diagnosis is made after that. It is very trustworthy for obvious reasons.
Read Full NewsAn AES study revealed the real-world persistence of fenfluramine in treating Lennox-Gastaut syndrome, highlighting patient demographics and treatment trends.
Final safety data from an open-label study presented at AES 2025 supported long-term fenfluramine use in pediatric and adult patients with Dravet syndrome or Lennox-Gastaut syndrome.
Low-Intensity Ultrasound Brain Stimulation Safely Reduces Depression Symptoms
Exercise May Be as Effective as Therapy for Alleviating Depression Symptoms
Parental Illness Perceptions Drive Poor QoL in Children with Food Allergies
Young Adults With Glomerular Disease May Require Distinct Care
Q4 2025 Recap: Nephrology News and Updates
1.
Glioblastoma treatment breakthrough shows promise
2.
MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC
3.
Study suggests exercise could reduce breast cancer recurrence
4.
Off-the-Shelf Drug Matches CAR-T Effects in Refractory Lupus
5.
Daily physical activity, even at light intensities, linked to lower cancer risk
1.
Lentigo Maligna Melanoma: Everything You Need To Know about This Skin Cancer
2.
Pediatric Oncology at the Cutting Edge: From Early Diagnosis to Lifesaving Therapies
3.
Advancements in Survival Mechanisms and Prognostic Determinants in Acute Myeloid Leukemia
4.
HPV Infection Review: Epidemiology, Risks, and Therapeutic Advances for Clinicians
5.
Case Study: Diagnostic and Therapeutic Challenges in Aplastic Anemia Mimicking Hypoplastic Myelodysplastic Syndrome
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
2.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation